4 Dod

CIN No:- L24230PB2006PLC030341

GST No:- 02AAHCA5390H27T ANG LIFESCIENCES INDIA LIMITED

Ref. NO. ...sseseseee Date...)4s)1: 2019.

To

Department of Corporate Services,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Un-Audited Standalone Financial Results for the Half Year ended September 30, 2019

Dear Sir/ Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015,

please find enclosed herewith the Un-Audited Financial Results of the Company for the Half Year ended

September 30, 2019 and the Statement of Assets and Liabilities as at September 30, 2019 as approved

by Board of Directors in its meeting held on November 14, 2019 along with the Limited Review Report

issued by M/s Ajay K Khanna & Co., Statutory Auditors of the Company.

Kindly take this information on your record.

Thanking You,

Regd. Office : SCO-113, Factory: . DARBARA COMPLI Village: Kishanpura, First Floor, oe Nalagarh Road, Ranjit Avenue, Amritsar.

Tehsil: Baddi, Ph. 0183-5133455, 5133458 Distt.: Solan, E mail :- operations@anglifesciences.com HP-174101 q LY website : www.anglifesciences.com

_ Ajay K Khanna & Co. CHARTERED ACCOUNTANTS

OFFICE : 2, Near Medcard Hospital, Tarn Taran Road, Amritsar - 143022

C.A. Bhupinder Singh B.COM, FCA, DISA (ICAI)

Ph.: 0183-5027845 (M) +91-9888307845

INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL

RESULTS FOR THE HALF YEAR ENDED 30™ SEPTEMBER, 2019

Review Report to

The Board of Directors,

ANG Lifesciences India Limited

SCO 113, Darbara Complex,

First Floor, B-Block,

Ranjit Avenue, Amritsar-143001

We have reviewed the accompanying statement of unaudited financial results of ANG Lifesciences India

Limited for the half year ended on 30 September, 2019. This statement is the responsibility of the

Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue

a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements

(SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the

Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan

and perform the review to obtain moderate assurance as to whether the financial statements are free of

material misstatement. A review is limited primarily to inquiries of company personnel and analytical

procedures applied to financial data and thus provides less assurance than an audit. We have not

performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe

that the accompanying statement of unaudited financial results prepared in accordance with applicable

accounting standards and other recognized accounting practices and policies has not disclosed the

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it

contains any material misstatement.

For Ajay K Khanna & Co. _

Chartered Accountants...

Yo.

</ WA *)\ x | = a

(Bhupinder Singh)<: \w\\° 513899 g| Partner

M. No. 513899

FRN: 012303N

unin: 19S 1 3899AAAAKH 55 16 Place: Amritsar

Date: 14.11.2019

www.xpertsalahkar.com, E-mail: cabhupinder29@gmail.com

ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

AUDITED STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED AND THE YEAR ENDED 30TH SEPTEMBER, 2019

(In Lacs)

For the

Half Year Ended year ended

Particulars

30.09.2019 31.03.2019 30.09.2018 31.03.2019

Unaudited Audited Unaudited Audited

|.]Revenue from operations 5862.99 6736.31 5433.67] 12169.98

Il. |Other income 12.57 14.94 8.33 23.27

Ill.| Total Revenue (I + Il) 5875.56 6751.25 5442.00 12193.25

IV.|Expenses:

(a) Cost of materials consumed 4272.07 4840.53 4048.12 8888.65

(b) Changes in Inventories 56.90 -93.89 -10.66 -104.55

(c) Employee benefits expense 267.70 323.44 315.69 639.13

(d) Finance costs 148.86 132.76 101.51 234.27

(e) Depreciation and amortization expense 54.83 56.88 55.49 112.37

(f) Other expenses 678.57 1017.99 594.52 1612.51

Total expenses 5478.93 6277.71 5104.67} 11382.38

Profit before exceptional and extraordinary items

V.}and tax (III-IV) 396.63 473.54 337.33 810.87

VI.|Exceptional items 0.00 0.00 0.00 0.00

Vil. |Profit before extraordinary items and tax (V - VI) 396.63 473.54 337.33 810.87

VIIL. |Extraordinary Items 0.00 0.00 0.00 0.00

IX.|Profit before tax (VII- VIII) 337.33 473.54 337.33 810.87

X|Tax expense: 0.00 0.00 0.00 0.00

(1) Current tax 112.35 170.12 66.41 236.53

(2) Deferred tax -0.12 2.74 0.00 2.74

(3) Mat Credit Entitlement 0.00 6.70 0.00 6.70

Profit (Loss) for the period from continuing

X!}operations (VII-VIII) 284.40 293.98 270.92 564.90

XII]Profit/ (loss) from discontinuing operations 0.00 0.00 0.00 0.00

XIIl]Tax expense of discontinuing operations 0.00 0.00 0.00 0.00

Profit/(loss) from Discontinuing operations

XIV| (after tax) (XII-XIII) 284.40 293.98 270.92 564.90

XV|Profit (Loss) for the period (XI + XIV) 284.40 293.98 270.92 564.90 XVI|Earnings per equity share:

(a) Basic & Diluted (Rs.) 5.49 5.67 5.23 10.90 (b) Diluted (Rs.) 5.49 5.67 5.23 10.90

Notes :

1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their

meeting held on November 14, 2019.

2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting

Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule7 of the

Companies (Accounts) Rules 2014 are not applicable.

3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to

confirm the figures in the current period.

4) As per MCA Notification dated 16.02.2015, the Companies whose shares are listed on SME exchange as referred in

ChapterXB of SEBI(Issue of Capital Disclosure requirements) Regulations 2009 are exempted from the compulsory

requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not

adopted IND -AS for prepartion of Financials Results.

Date : 14.11.2019

Place : Amritsar

ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com

Website : www.anglifesciences.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Amout in Lacs)

Sri For the year For the year

No. Particulars ended ended

30.09.2019 31.03.2019 |. |EQUITY AND LIABILITIES

1|Shareholders’ funds

(a) Share capital 518.33 518.33 (b) Reserves and surplus 2642.80 2358.40 Sub-total-Shareholders' Fund 3161.13 2876.73

2|Non-current liabilities

(a) Long-term borrowings 635.77 627.76 (b) Other Long-term liabilities 289.58 290.08 (c) Deferred Tax Liabilities (Net 39:57 39.69 (d) Long-term Provisions 14.06 15.06

Sub-total-non Current Liabilities 978.98 972.60 3|Current liabilities

(a) Short Term Borrowings 1297.46 1241.45

(b) Trade Payables 2006.48 2181.46

(c) Other current liabilities 743.16 592.45

(d) Short-term provisions 281.72 225.08

Sub-total-Current Liabilities 4328.82 4240.44 TOTAL EQUITY AND LIABILITIES 8468.94 8089.76

ll. |ASSETS

Non-current assets

1\(a) Property, Plant and Equipment

(i) Tangible assets 2133.84 2075.94

(b) Deferred Tax Assets (Net 0.00 0.00

(c) Other non-current assets 16.13 15.92

(d) Other non-current Investments 2.00 2.00

Sub-total-non Current Assets 2151.97 2093.86

2|Current assets

(a) Inventories 566.40 653.73

(b) Trade receivables 4717.71 4174.87

(c) Cash and cash equivalents 248.13 437.15

(d) Short-term loans and advances 784.72 730.15

Sub-total-Current Assets 6316.96 5995.90

8468.94 8089.76

TOTAL ASSETS --= See acgompspy ES eins part of the financial statements. O

7, Sciences In is mited

Oy

rs Ss)

5 cy (Managing

Rajesh Gupta

(DIN : 01423407)

Date : 14.11.2019

Place : Amritsar

ANG Life Sciences India Ltd.

Registered Office : 113, First Floor, Darbara Complex, Ranjit Avenue, Amritsar

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER 2019

Particulars As at 30th Year ended

September 2019 {31st March 2019

(A) }CASH FLOW FROM OPERATING ACTIVITIES

1]Net Profit/(loss) before extraordinary items and Tax 284.40 564.90 2]Adjustments for ;

a) Depreciation and Amortisation 54.83 192;37 b) Finance Cost Expenses 148.86 234.27

c) Current Taxes 112.35 236.53 d) Deferred Taxes -0.12 2.74 e) Premininary Expenses 0.00 0.00

f) MAT Credit 0.00 0.00 Operating Profit before working capital Changes (1+2) 600.33 1150.81

3}Adjustments for Working Capital Changes ;

(i) (Increase)/decrease Operating Assets

a) Trade Receivables -542.84 -959.84 b) Short Term Loans and Advances -54.57 -179.94 c) Other Current Assets 0

(ii) Increase/(Decrease) in Operating Liabilities

a) Trade Payables -174.98 -50.06 b) Short Term Provisions 56.65 120.76 c) Other Current Liabilities 150.71 23.59 d) Other Long Term Liability -0.50 140.26 e) Long Term Provisions -1.00 15.06

f) Short Term Borrowings 56.01 601.55

0.00

(iii) (Increase)/Decrease in inventories 87.33 120.55

177.42 982.74 Less : Income Tax Paid (Net) -112.35 -236.53

Net Cash from Operating Activities (A) 64.77 746.21

(B) JCASH FLOW FROM INVESTING ACTIVITIES

a) Purchase of Fixed Assets including Capital W.I.P. -112.73 -84.18 b) Change in Non-Current Assets -0.21 7.01 c) Change in Non-Current Investment 0

Net Cash from Investing Activities (B) -77.17

(C) }CASH FLOW FROM FINANCING ACTIVITIES

a) b) c) d) e)

f) g)

Interest paid

Proceeds from Long Term Borrowings

Repayment of Long Term Borrowings

Proceeds from issue of Share Capital

Proceeds from Share Premium

Proceeds from sale of assets

Decrease in Capital Reserve

Net Cash from Financing Activities (C )

(D) |Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)

(E) |Cash & Cash Equivalents at the beginning of the year (F) |Cash & Cash Equivalents at the end of the year

-148.86 -234.27

43.00 43.00

-34.99 -183.56

0.00 0.00

0.00 0.00

0.00 0.00

0.00 -5.00

-140.85 -379.84

-189.02 289.20

437.15 147.94

248.13 437.15 Note : 1 Components of Cash & Cash Eqivalents

Cash in hand

Balance with Schedule Banks

in Current Accounts

2. The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the

Accounting Standard-3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India

3. The previous year's figures have been regrouped whereever necessary.

For ANG Life

(Managing Directorp

Rajesh Gupta

(DIN : 01423407)

Date : 14.11.2019

Place : Amritsar